Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05824364
Other study ID # ENEA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 20, 2023
Est. completion date December 31, 2024

Study information

Verified date September 2023
Source Fondazione Don Carlo Gnocchi Onlus
Contact Nuccia Morici, MD
Phone 00390240308122
Email nmorici@dongnocchi.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Registry-based randomized clinical trial (RRCT) to assess the safety and efficacy of two different schemes of exercise training in patients who have recently undergone heart transplantation


Description:

40 patients who achieved Heart transplantation (HTx) will be randomized in a pilot study to 4 weeks of on-site standard CR (control arm) versus two-four weeks of on-site CR followed by 12 weeks of telerehabilitation (experimental arm). Both surrogate endpoints [cardiometabolic equivalents (Vo2 peak)] and clinical endpoint [primary outcome defined as acute rejection, hospitalization for heart failure, stroke, myocardial infarction, all-cause mortality, at the longest follow-up available (minimum 6-month follow-up)] will be evaluated. The rehabilomic approach will be applied in order to identify specific patients' phenotype. To identify the potential variations of circulating molecules levels that could be indicators of the rehabilitation outcome and/or progression of the disease, the research team will focus on the analysis of extracellular vesicles (EVs) isolated from the serum of the 40 patients at admission (T0) and after cardiac rehabilitation (T1). In particular, researchers will detect and analyze the relative amount of serum EVs derived from platelets, endothelium, cardiomyocytes, and macrophages, as their levels are reported to be associated with the occurrence of heart failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2024
Est. primary completion date October 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All the patients admitted in the on-site CR after HTx Exclusion Criteria: - unable to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
telerehabilitation
Telerehabilitation activites will be tested with the aim to provide 1) continuation of rehabilitative care, focused on physical training and patients'monitoring , and 2) information in the mid-term about study goals.
rehabilomic
blood withdrawal (10 ml of blood, two tubes of 5 ml for serum isolation): at the hospital admission at the Cardiac Rehabilitation Unit of IRCCS Fondazione Don Gnocchi of Milan (T0) and after the rehabilitative treatment (T1)

Locations

Country Name City State
Italy IRCCS Fondazione Don Gnocchi, Milan Milan

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Don Carlo Gnocchi Onlus

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular events Incidence of acute rejection, Rate of hospitalization for heart failure, Incidence of stroke, Incidence of myocardial infarction and incidence of all-cause mortality 6-months
Secondary Vo2 peak cardiometabolic equivalents (Vo2 peak) 6-months
Secondary extracellular vesicles (EVs) analysis with Surface Plasmon Resonance imaging (SPRi) EVs will be isolated from blood, characterized by standard procedures and injected on the SPRi biosensor for the differential quantification of multiple EV subfamilies. The expression of a secondary antigen will be evaluated on the surface of immobilized EVs. up to 4 weeks
Secondary EuroQol 5-Dimension (EQ-5D-5L) The EQ-5D-5L is a generic questionnaire measuring five domains of current health-related quality of life, where a higher index score indicates higher health-related quality of life. 6-months
Secondary Short Form 36 (SF36) The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. 6-months
Secondary Hospital Anxiety and Depression Scale (HADS) The HADS is a 14-item generic questionnaire measuring symptoms of anxiety and depression within the last week. 6-months
See also
  Status Clinical Trial Phase
Completed NCT02964026 - Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients N/A
Active, not recruiting NCT05096299 - OCS Heart EXPAND + CAP Continued Follow-Up
Completed NCT02323321 - International EXPAND Heart Pivotal Trial N/A
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Completed NCT03150095 - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates N/A
Active, not recruiting NCT02554578 - Impact of mHealth in Heart Transplant Management N/A
Terminated NCT03346278 - Text Message Intervention to Improve Cardiac Rehab Participation N/A
Active, not recruiting NCT05741723 - OCS DCD Heart + CAP Continued Follow-Up
Completed NCT03831048 - Donors After Circulatory Death Heart Trial N/A
Completed NCT04615182 - Donor After Circulatory Death Heart CAP Trial N/A
Completed NCT02597543 - Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction Phase 4
Not yet recruiting NCT05025774 - Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Enrolling by invitation NCT05390411 - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial N/A
Recruiting NCT04770012 - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Phase 3
Terminated NCT01769443 - Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation Phase 2
Completed NCT00466804 - Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients N/A
Not yet recruiting NCT05459181 - HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC) N/A
Terminated NCT01485757 - Prospective L-arginine Study Phase 1
Active, not recruiting NCT01186250 - Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation Phase 2
Completed NCT00812786 - Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients Phase 4